Immediate Impact
1 by Nobel laureates 62 standout
Citing Papers
Advances in targeting histone deacetylase for treatment of solid tumors
2024 Standout
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Works of Andreas Mueller being referenced
Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Andreas Mueller | 64 | 40 | 46 | 66 | 56 | 24 | 231 | |
| Hana Park | 28 | 8 | 114 | 45 | 52 | 24 | 277 | |
| Toulsie Ramtohul | 154 | 34 | 23 | 104 | 36 | 29 | 282 | |
| Sun Woong Kim | 48 | 15 | 130 | 48 | 51 | 24 | 289 | |
| Kozo Masuda | 109 | 42 | 64 | 96 | 66 | 20 | 295 | |
| Yi-Zhuo Wang | 43 | 24 | 10 | 13 | 33 | 24 | 166 | |
| Paulina Cybulska | 96 | 38 | 21 | 27 | 6 | 28 | 294 | |
| Sze Wah Samuel Chan | 106 | 69 | 8 | 54 | 29 | 27 | 251 | |
| Antonino Romanzo | 34 | 32 | 13 | 18 | 83 | 18 | 163 | |
| Abdulazeez Salawu | 115 | 81 | 8 | 13 | 15 | 27 | 251 | |
| Kusum Sharma | 18 | 52 | 41 | 13 | 26 | 23 | 248 |
All Works
Login with ORCID to disown or claim papers
Loading papers...